Scilex Holding Co
For the period ended Sep 30, 2024. Filed Jan 17, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Jan 17, 2025
SCLX$1.61-7.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(66,347) | $(92,931) |
| Adjustments to reconcile net loss to net cash proceeds from (used for) operating activities: | ||
| Depreciation and amortization | 3,042 | 3,112 |
| Amortization of debt issuance costs and debt discount | 94 | 34 |
| Non-cash operating lease cost | 547 | 330 |
| Stock-based compensation | 10,884 | 10,813 |
| (Gain) loss on derivative liability | (2,367) | 1,090 |
| Allocated expenses for warrant issuance cost | 2,526 | — |
| Change in fair value of debt and liability instruments | 11,961 | 4,197 |
| Allowances for expected credit losses | 1,186 | — |
| Other | 392 | 731 |
| Changes in operating assets and liabilities: | ||
| Accounts receivables, net | 1,831 | 4,808 |
| Inventory | 1,496 | (2,565) |
| Prepaid expenses and other | (2,857) | 1,072 |
| Other long-term assets | (30) | 804 |
| Accounts payable | 2,266 | 11,486 |
| Accrued payroll | (1,706) | 1,779 |
| Accrued expenses | 2,463 | 5,525 |
| Accrued rebates and fees | 52,051 | 34,907 |
| Other liabilities | (593) | (519) |
| Other long-term liabilities | (24) | 10 |
| Net cash proceeds from (used for) operating activities | 16,815 | (15,317) |
| Investing activities | ||
| Acquisition consideration paid in cash for Romeg intangible asset acquisition | (450) | (134) |
| Purchase of equity securities | (2,000) | — |
| Purchase of convertible promissory note from Denali | (30) | — |
| Purchase of property, plant and equipment | — | (29) |
| Net cash used for investing activities | (2,480) | (163) |
| Financing activities | ||
| Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement | 156 | 27,589 |
| Proceeds from issuance of Convertible Debentures | — | 24,000 |
| Proceeds from issuance of Revolving Facility | 93,389 | 52,550 |
| Proceeds from issuance of FSF Deposit | 10,000 | — |
| Repayment of Revolving Facility | (96,189) | (45,272) |
| Repayment of Oramed Note | (36,700) | — |
| Cash consideration paid in connection with warrant repurchase | (300) | — |
| Transaction costs paid related to the Business Combination | — | (1,372) |
| Repayment of Convertible Debentures | (4,375) | (10,953) |
| Payments of debt issuance costs | — | (380) |
| Disbursement of funds to Sorrento | — | (20,000) |
| Cash consideration paid in connection with share repurchase | — | (10,000) |
| Transaction costs paid in connection with share repurchase | — | (1,987) |
| Proceeds from issuance of shares under Bought Deal Offering and Registered Direct Offering | 25,000 | — |
| Payments of Bought Deal Offering and Registered Direct Offering issuance costs | (2,844) | — |
| Proceeds from stock options and warrants exercised and ESPP | 915 | 1,101 |
| Net cash (used for) proceeds from financing activities | (10,948) | 15,276 |
| Net change in cash, cash equivalents and restricted cash | 3,387 | (204) |
| Cash, cash equivalents and restricted cash at beginning of period | 4,729 | 2,184 |
| Cash, cash equivalents and restricted cash at end of period | $8,116 | $1,980 |
| Supplemental disclosure: | ||
| Non-cash investing and financing activities | ||
| Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement | $— | $1,869 |
| Issuance costs related to Bought Deal Offering and Registered Direct Offering included in accrued expenses and account payables | $1,430 | $— |
| Conversion of Convertible Debentures into common stock | $— | $7,735 |
| Right-of-use assets obtained in exchange for operating lease liabilities with lease modification | $— | $2,523 |
| Oramed Note issuance at fair value | $— | $106,252 |
| Other non-cash consideration in connection with share repurchase | $— | $26,154 |
| Excise tax in connection with share repurchase included in accrued expenses | $— | $1,375 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.